Therapeutic Solutions International Develops Gene Silencing Therapy for Acute Respiratory Distress Syndrome
Therapeutic Solutions International (OTC-PINK:TSOI) announced a patent filing covering gene silencing for treating Acute Respiratory Distress Syndrome (ARDS), a significant cause of mortality.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
The Company currently is running a Phase III trial treating COVID-19 induced ARDS but has requested permission from the FDA to expand to ARDS caused by other precipitating factors.
The new data demonstrates feasibility of selectively silencing genes in the lung associated with mortality caused by ARDS, as well as a potent survival advantage in treated versus untreated mice. An approximately
The Company plans to continue development of this approach, which is attempted to synergize with the current regenerative medicine programs currently underway.
“We are committed to making a significant impact in the lives of patients with ARDS. As part of that commitment, we need to constantly push the limits of medicine and science,” said Dr.
“The value of a biotechnology company is in its programs and intellectual property. As our ongoing Phase III continues, our team is brilliantly leveraging this waiting period to continually advance our science. This is what patients and investors count on use to do,” said
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20220829005264/en/
ir@tsoimail.com
Source: